Bayer's Hemophilia A Portfolio Boosted by Jivi's EU Approval

 
• By Sten Stovall
  
Protein
Jivi is a longer-acting Factor VIII therapy designed to cut the number of infusions needed • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from New Products

More from Scrip